CRISPR reportedly repaired a faulty gene inside patients for the first time in 2025

In October 2026, News from Science revisited a 2025 report, not a new clinical result. Science's Jocelyn Kaiser described Beam Therapeutics' experimental gene-repair infusion in nine patients with alpha-1 antitrypsin deficiency. Corrected AAT protein levels rose while flawed protein levels fell. Science cited an assessment that damage should be halted in some cases, but did not report measured improvement in lung or liver damage.